Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.428
Filtrar
1.
Xenotransplantation ; 31(5): e12884, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39410785

RESUMEN

This report summarizes the content of a debate sponsored by eGenesis Bio, organized by the International Xenotransplantation Association (IXA), and attended by more than 150 delegates in the context of the IPITA-IXA-CTRMS Joint Congress held in San Diego in October 2023. The debate centered around two important immunological topics relating to xenotransplantation. The first was a debate relating to the statement that "HLA-sensitized patients are at higher risk for rejecting a pig xenograft." Stuart Knechtle provided evidence to support this statement and Massimo Mangiola opposed it. Before the debate, a majority (>80%) of the audience agreed with this statement. After listening to the debate, this percentage was reduced to approximately 60%. The second debated statement was "Recipients of pig xenografts who develop anti-pig antibodies are at higher risk for rejecting a subsequent allograft." This was proposed by A. Joseph Tector and opposed by Léo H. Bühler. Before the debate, once again a majority of the audience (approximately 60%) believed that prior sensitization to a pig xenograft would be detrimental to the survival of a subsequent allograft. However, after listening to the debate, only about 40% believed this statement to be correct. The topics discussed remain complex and answers are not yet conclusive. However, the present evidence suggests that allosensitization may prove detrimental to subsequent xenotransplantation, whilst sensitization to pig antigens may not be detrimental to subsequent allotransplantation.


Asunto(s)
Rechazo de Injerto , Xenoinjertos , Trasplante Heterólogo , Trasplante Heterólogo/métodos , Animales , Humanos , Porcinos , Rechazo de Injerto/inmunología , Xenoinjertos/inmunología , Trasplante de Órganos/métodos , Trasplante Homólogo/métodos , Supervivencia de Injerto/inmunología
2.
HLA ; 104(3): e15675, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39247974

RESUMEN

The determination of panel reactive antibodies (cPRA) scores plays a critical role in assessing the immunological compatibility between organ transplant recipients and potential donors. Traditional cPRA methods focus on a limited number of HLA loci using physical cytotoxicity tests. However, advancements such as the Luminex single antigen (LSA) assay, which uses mean fluorescence intensity (MFI) of individualised HLA antigens for antibody evaluation, provide a foundation for a more precise assessment. We developed cPRAdictor, a novel cPRA calculation tool using a large series of HLA-type individuals in France with NGS. cPRAdictor was applied to a cohort of 5962 kidney transplant candidates in Paris. We analysed how extending the range of HLA specificities could affect cPRA values. Implementing cPRAdictor revealed and allowed quantification of the significant discrepancies in cPRA values that appeared when HLA loci C and DP, and antigen-specific antibodies were taken into account. Notably, over 43% of the immunised transplant candidates showed an increase in calculated cPRA values when considering C/DP loci and antigen-specific antibodies, negatively impacting their eligibility and prioritisation in the transplantation programme. These findings highlight the necessity of revisiting cPRA calculation methodologies to include a broader spectrum of immunological data, as more exhaustive and precise information regarding anti-HLA antibodies in patients' sera and donor and recipient HLA typing are available prospectively. This will strongly improve both accuracy and equity at the organ allocation step, especially for highly sensitised candidates for whom organ offers are very limited in number.


Asunto(s)
Antígenos HLA , Prueba de Histocompatibilidad , Isoanticuerpos , Listas de Espera , Humanos , Prueba de Histocompatibilidad/métodos , Antígenos HLA/inmunología , Isoanticuerpos/sangre , Isoanticuerpos/inmunología , Paris , Trasplante de Riñón , Donantes de Tejidos , Trasplante de Órganos/métodos , Histocompatibilidad
3.
Transpl Int ; 37: 13215, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39267617

RESUMEN

Solid organ transplantation has progressed rapidly over the decades from the first experimental procedures to its role in the modern era as an established treatment for end-stage organ disease. Solid organ transplantation including liver, kidney, pancreas, heart, and lung transplantation, is the definitive option for many patients, but despite the advances that have been made, there are still significant challenges in meeting the demand for viable donor grafts. Furthermore, post-operatively, the recipient faces several hurdles, including poor early outcomes like primary graft dysfunction and acute and chronic forms of graft rejection. In an effort to address these issues, innovations in organ engineering and treatment have been developed. This review covers efforts made to expand the donor pool including bioengineering techniques and the use of ex vivo graft perfusion. It also covers modifications and treatments that have been trialed, in addition to research efforts in both abdominal organs and thoracic organs. Overall, this article discusses recent innovations in machine perfusion and organ bioengineering with the aim of improving and increasing the quality of donor organs.


Asunto(s)
Bioingeniería , Preservación de Órganos , Trasplante de Órganos , Perfusión , Humanos , Perfusión/métodos , Bioingeniería/métodos , Trasplante de Órganos/métodos , Preservación de Órganos/métodos , Rechazo de Injerto/prevención & control , Donantes de Tejidos/provisión & distribución
4.
Adv Drug Deliv Rev ; 213: 115429, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39142608

RESUMEN

Drug delivery strategies for local immunomodulation hold tremendous promise compared to current clinical gold-standard systemic immunosuppression as they could improve the benefit to risk ratio of life-saving or life-enhancing transplants. Such strategies have facilitated prolonged graft survival in animal models at lower drug doses while minimizing off-target effects. Despite the promising outcomes in preclinical animal studies, progression of these strategies to clinical trials has faced challenges. A comprehensive understanding of the translational barriers is a critical first step towards clinical validation of effective immunomodulatory drug delivery protocols proven for safety and tolerability in pre-clinical animal models. This review overviews the current state-of-the-art in local immunomodulatory strategies for transplantation and outlines the key challenges hindering their clinical translation.


Asunto(s)
Sistemas de Liberación de Medicamentos , Humanos , Animales , Inmunomodulación , Agentes Inmunomoduladores/administración & dosificación , Inmunosupresores/administración & dosificación , Trasplante de Órganos/métodos , Investigación Biomédica Traslacional
5.
Wiad Lek ; 77(6): 1284-1290, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39106393

RESUMEN

In view of rapid advancements in the field of transplantology, emerging solutions in tissue procurement for transplantation became a crucial area of research. Tissue transplantation plays a notable role in improving the quality of life for patients afflicted with various ailments, and the increasing number of transplants necessitates the exploration of innovative procurement methods. This study examines a new direction in transplantology, placing focus on innovative approaches to tissue procurement and discussing the commonly used method of "ex mortuo," i.e., retrieving organs from deceased donors. Given the growing demand for organs, the paper discusses the innovative approach slowly emerging as 3D bioprinting. The paper discusses the key challenges associated with the use of this method in transplantology, including issues of biocompatibility, vascularization, and integration with the immune system. The paper also discusses the latest scientific achievements in the field, such as the first transplants of bioprinted organs, demonstrating the practical application of this technology in medicine. It is also the analysis of the ethical, social, and legal aspects related to these new solutions. The article provides a comprehensive overview of the latest trends in transplantology and presents a holistic view of the current state of knowledge and prospects for development in this pivotal area of medicine.


Asunto(s)
Obtención de Tejidos y Órganos , Humanos , Obtención de Tejidos y Órganos/métodos , Trasplante de Órganos/métodos , Trasplante de Órganos/tendencias , Impresión Tridimensional , Bioimpresión , Donantes de Tejidos
6.
Physiology (Bethesda) ; 39(6): 0, 2024 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-38954427

RESUMEN

Women suffering from absolute uterine factor infertility (AUFI), due to either lack of a uterus or one unable to sustain neonatal viability, presented as one of the last frontiers in conquering infertility. Following systematic animal research for over a decade, uterus transplantation was tested as a treatment for AUFI in 2012, which culminated in the first human live birth in 2014. The development of uterus transplantation from mouse to human has followed both the Moore criteria for introduction of a surgical innovation and the IDEAL concept for evaluation of a novel major surgical procedure. In this article we review the important preclinical animal and human studies that paved the way for the successful introduction of human uterus transplantation a decade ago. We discuss this in the context of the Moore criteria and describe the different procedures of preparation, surgeries, postoperative monitoring, and use of assisted reproduction in human uterus transplantation. We review the worldwide activities and associated results in the context of the IDEAL concept for evaluation of surgical innovation and appraise the ethical considerations relevant to uterus transplantation. We conclude that rigorous application of the Moore criteria and strict alignment with the IDEAL concept have resulted in the establishment of uterus transplantation as a novel, safe, and effective infertility therapy that is now being used worldwide for the treatment of women suffering from AUFI.


Asunto(s)
Infertilidad Femenina , Útero , Humanos , Útero/trasplante , Femenino , Animales , Infertilidad Femenina/cirugía , Infertilidad Femenina/terapia , Investigación Biomédica Traslacional/tendencias , Trasplante de Órganos/métodos , Trasplante de Órganos/tendencias
7.
Chirurgie (Heidelb) ; 95(8): 610-617, 2024 Aug.
Artículo en Alemán | MEDLINE | ID: mdl-39052038

RESUMEN

The use of machine perfusion in solid organ transplantation has developed tremendously worldwide in recent years. Although the number of randomized controlled trials in the field of organ preservation is still limited, machine perfusion has been shown to be superior to static cold storage of donor organs. Various devices for clinical use with hypothermia or normothermia are already available for most organs. Whether and which perfusion strategy is superior to the others is the subject of current clinical research. This also applies to the further evaluation of possible synergistic effects in the sequential use of the various protocols. The common goal of all dynamic perfusion technologies is to optimize organ preservation between removal and transplantation. By testing the quality of marginal donor organs prior to transplantation, it should also be possible to use these organs without exposing the patient to increased risk. This can lead to a significant expansion of the donor pool. This is particularly important in Germany, where there is an ongoing shortage of organs and restrictive legislation regarding the expansion of the donor pool. Furthermore, the perfusion technology offers the possibility to serve as a platform for other ex situ and in situ therapies on isolated organs. In addition to the conditioning of pre-damaged organs for transplantation, this could lead to further applications in the context of targeted organ therapies and also to improved transplant logistics in the future.


Asunto(s)
Preservación de Órganos , Perfusión , Humanos , Perfusión/métodos , Perfusión/instrumentación , Preservación de Órganos/métodos , Preservación de Órganos/instrumentación , Trasplante de Órganos/métodos
8.
Gastroenterol Clin North Am ; 53(3): 441-452, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39068005

RESUMEN

This study explores intestinal transplantation (ITx) as a viable treatment option for intestinal failure (IF). Historical development, donor and recipient considerations, surgical techniques, immunosuppression, and outcomes, are reviewed with particular emphasis to the value of living donor ITx. The review highlights the evolution of ITx and emphasizes the ongoing need for patient-specific selection processes. In the realm of pediatric ITx, the article underlines the significance of early intervention to mitigate IF-related liver disease. Overall, it provides a comprehensive overview of this life-saving procedure.


Asunto(s)
Intestinos , Donadores Vivos , Humanos , Intestinos/trasplante , Insuficiencia Intestinal/cirugía , Trasplante de Órganos/métodos
9.
Gastroenterol Clin North Am ; 53(3): 453-459, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39068006

RESUMEN

The history of intestinal transplantation can be traced back to the turn of the twentieth century. Although advancements have been made, the intestine still presents a greater challenge to transplantation than does that of other solid organs, experiencing higher rates of graft rejection and lower long-term survival. Increasingly, intestinal re-transplantation (re-ITx) is seen as a viable option and is now the fourth most common indication for ITx. Changes to immunosuppression protocols, technical modifications, and infectious disease monitoring have contributed to improved outcomes. The authors review the literature on re-ITx in regard to the history, management considerations, and future directions.


Asunto(s)
Rechazo de Injerto , Intestinos , Reoperación , Humanos , Intestinos/trasplante , Rechazo de Injerto/prevención & control , Inmunosupresores/uso terapéutico , Trasplante de Órganos/métodos , Supervivencia de Injerto
11.
Transplantation ; 108(8): 1669-1680, 2024 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-39012953

RESUMEN

BACKGROUND: Thoracoabdominal normothermic regional perfusion (TA-NRP) has emerged as a powerful technique for optimizing organ procurement from donation after circulatory death donors. Despite its rapid adoption, standardized guidelines for TA-NRP implementation are lacking, prompting the need for consensus recommendations to ensure safe and effective utilization of this technique. METHODS: A working group composed of members from The American Society of Transplant Surgeons, The International Society of Heart and Lung Transplantation, The Society of Thoracic Surgeons, and The American Association for Thoracic Surgery was convened to develop technical guidelines for TA-NRP. The group systematically reviewed existing literature, consensus statements, and expert opinions to identify key areas requiring standardization, including predonation evaluation, intraoperative management, postdonation procedures, and future research directions. RESULTS: The working group formulated recommendations encompassing donor evaluation and selection criteria, premortem testing and therapeutic interventions, communication protocols, and procedural guidelines for TA-NRP implementation. These recommendations aim to facilitate coordination among transplant teams, minimize variability in practice, and promote transparency and accountability throughout the TA-NRP process. CONCLUSIONS: The consensus guidelines presented herein serve as a comprehensive framework for the successful and ethical implementation of TA-NRP programs in organ procurement from donation after circulatory death donors. By providing standardized recommendations and addressing areas of uncertainty, these guidelines aim to enhance the quality, safety, and efficiency of TA-NRP procedures, ultimately contributing to improved outcomes for transplant recipients.


Asunto(s)
Consenso , Preservación de Órganos , Perfusión , Humanos , Perfusión/normas , Perfusión/métodos , Preservación de Órganos/normas , Preservación de Órganos/métodos , Donantes de Tejidos/provisión & distribución , Trasplante de Órganos/normas , Trasplante de Órganos/métodos , Selección de Donante/normas , Obtención de Tejidos y Órganos/normas , Obtención de Tejidos y Órganos/métodos
12.
Gastroenterol Clin North Am ; 53(3): 413-430, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39068003

RESUMEN

In this review, the authors outlined concepts and strategies to achieve immune tolerance through inducing hematopoietic chimerism after solid organ transplantation and introduced challenges and opportunities in harnessing two-way alloresponses to improve outcomes after intestinal transplantation (ITx). Next, the authors discussed the dynamics and phenotypes of peripheral blood and intestinal graft T-cell subset chimerism and their association with outcomes. The authors also summarized studies on other types of immune cells after ITx and their potential participation in chimerism-mediated tolerance. The authors further discussed strategies and future directions to promote chimerism-associated tolerance after ITx to overcome rejection and minimize immunosuppression.


Asunto(s)
Intestinos , Quimera por Trasplante , Humanos , Intestinos/trasplante , Intestinos/inmunología , Quimera por Trasplante/inmunología , Tolerancia al Trasplante/inmunología , Quimerismo , Trasplante de Órganos/métodos , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Tolerancia Inmunológica
13.
J Pharm Biomed Anal ; 247: 116271, 2024 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-38850850

RESUMEN

Sirolimus (SRL) is commonly used in transplant patients to prevent organ transplant rejection. The current guidelines recommend to perform SRL therapeutic drug monitoring regularly to improve treatment outcomes and avoid adverse effects. Consequently, a precise and accurate method for determining SRL is crucial in clinical practice. Currently, liquid chromatography-tandem mass spectrometry (LC-MS/MS) and immunoassays have been widely adopted for determining SRL concentrations. However, previous studies have shown that immunoassays exhibit a positive bias compared to LC-MS/MS. As the new updated version of the EMIT-based Viva-E® System (SVPS), this study aims to compare SRL blood concentrations measured by the SVPS and LC-MS/MS. The residual whole-blood samples obtained from transplant patients were simultaneously analyzed using the SVPS and LC-MS/MS, respectively. The correlation between the two assays was analyzed using the linear regression analysis and Deming linear regression. The Pearson correlation coefficient and Intraclass correlation coefficient (ICC) analysis were executed. The Paired Wilcoxon test and Bland-Altman analysis were performed to assess the concordance between the two methods. The SVPS considerably increased SRL concentration value by 46.62 % as compared to the LC-MS/MS method. When SRL concentrations measured by the SVPS were above 4.0 ng/mL, there was no significant difference between the corrected SVPS concentrations after using the Deming linear regression equation, indicating their interchangeability. Given the significant disparities observed between EMIT and LC-MS/MS, it is crucial to indicate the methodology and instruments in both TDM reports and future clinical guidelines. Our study also provides the conversion formulas between the SVPS and LC-MS/MS, which can be applied as a reference for different clinical centers.


Asunto(s)
Monitoreo de Drogas , Inmunosupresores , Trasplante de Órganos , Sirolimus , Espectrometría de Masas en Tándem , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , China , Cromatografía Liquida/métodos , Monitoreo de Drogas/métodos , Pueblos del Este de Asia , Inmunoensayo/métodos , Inmunosupresores/sangre , Cromatografía Líquida con Espectrometría de Masas , Trasplante de Órganos/métodos , Reproducibilidad de los Resultados , Sirolimus/sangre , Espectrometría de Masas en Tándem/métodos
14.
Artif Organs ; 48(8): 805-806, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38924112

RESUMEN

Transplantation has generally been focused on end-stage organ disease in adults. Scientists from Japan are now focusing on in utero transplantation in fetuses with congenital anomalies.


Asunto(s)
Trasplante de Tejido Fetal , Humanos , Femenino , Embarazo , Anomalías Congénitas/cirugía , Feto/cirugía , Enfermedades Fetales/cirugía , Trasplante de Órganos/métodos
15.
Ann Transplant ; 29: e943387, 2024 Jun 04.
Artículo en Inglés | MEDLINE | ID: mdl-38831572

RESUMEN

Despite continuous and rapid progress in the transplantation of cells, tissues, and organs, many patients die before receiving them. This is because of an insufficient number of donors, which leads to a significant disproportion between the need for donors and their availability. This review aims to present the possibilities offered by alternative therapies. We use the term "functional transplantology" to describe such alternative methods of transplantation that could help change the current state of transplantation medicine. Its purpose is not to replace a defective or removed organ with another but to replace its functions using complementary biological, mechanical, or biomechanical structures or devices. Implementation of many innovative solutions shown in the work for clinical applications is already a fact. In the case of others, it should be considered a future vision. We hope that the role of a defective or damaged tissue or a group of tissues will be taken over by different structures that are functionally complementary with the organ being substituted. Undoubtedly, developing the described methods based on functional transplantology will change the face of transplantation medicine. Thus, we show current trends and new directions of thinking and actions in transplantation medicine that combine technology and transplantology. The review considers the latest technologies, including 3D bioprinting, nanotechnology, cell encapsulation, and organoids. We discuss not only the advantages of new approaches but also the limitations and challenges that must be overcome to achieve significant progress in transplantation. That is the only option to provide a safe and efficient way of improving the quality of life of many patients.


Asunto(s)
Trasplante de Órganos , Humanos , Trasplante de Órganos/métodos , Trasplante de Órganos/tendencias , Terapias Complementarias/métodos , Ingeniería de Tejidos/métodos , Nanotecnología/métodos , Bioimpresión/métodos , Impresión Tridimensional
16.
Front Immunol ; 15: 1371554, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38846942

RESUMEN

Allograft rejection is a critical issue following solid organ transplantation (SOT). Immunosuppressive therapies are crucial in reducing risk of rejection yet are accompanied by several significant side effects, including infection, malignancy, cardiovascular diseases, and nephrotoxicity. There is a current unmet medical need with a lack of effective minimization strategies for these side effects. Extracorporeal photopheresis (ECP) has shown potential as an immunosuppression (IS)-modifying technique in several SOT types, with improvements seen in acute and recurrent rejection, allograft survival, and associated side effects, and could fulfil this unmet need. Through a review of the available literature detailing key areas in which ECP may benefit patients, this review highlights the IS-modifying potential of ECP in the four most common SOT procedures (heart, lung, kidney, and liver transplantation) and highlights existing gaps in data. Current evidence supports the use of ECP for IS modification following SOT, however there is a need for further high-quality research, in particular randomized control trials, in this area.


Asunto(s)
Rechazo de Injerto , Terapia de Inmunosupresión , Trasplante de Órganos , Fotoféresis , Fotoféresis/métodos , Humanos , Trasplante de Órganos/efectos adversos , Trasplante de Órganos/métodos , Rechazo de Injerto/prevención & control , Rechazo de Injerto/inmunología , Terapia de Inmunosupresión/métodos , Inmunosupresores/uso terapéutico , Inmunosupresores/efectos adversos , Supervivencia de Injerto
17.
Artif Organs ; 48(7): 794-799, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38693706

RESUMEN

The American Transplant Congress (ATC) 2023, held in San Diego, California, emerged as a pivotal platform showcasing the latest advancements in organ machine perfusion, a key area in solid organ and tissue transplantation. This year's congress, attended by over 4500 participants, including leading experts, emphasized innovations in machine perfusion technologies across various organ types, including liver, kidney, heart, and lung. A total of 85 abstracts on organ machine perfusion were identified. Noteworthy advancements included the use of normothermic machine perfusion in mitigating ex-situ reperfusion injury in liver transplantation, the potential of biomarkers in assessing organ quality, and the impact of machine perfusion on graft survival and ischemic cholangiopathy incidence. Kidney transplantation saw promising developments in novel preservation methods, such as subzero storage and pulsatile perfusion. Heart and lung sessions revealed significant progress in preservation techniques, including metabolic alterations to extend organ preservation time. The conference also highlighted the growing interest in machine perfusion applications in pediatric transplantation, multi-visceral organ recovery, Vascularized Composite Allotransplantation, and discussions on novel technologies for monitoring and optimizing perfusion protocols. Additionally, ATC 2023 included critical discussions on ethical concerns, legal implications, and the evolving definition of death in the era of machine preservation, illustrating the complex landscape of transplantation science. Overall, ATC 2023 showcased significant strides in machine perfusion and continued its tradition of fostering global knowledge exchange, further cementing machine perfusion's role as a transformative force in improving transplant outcomes and expanding the donor pool.


Asunto(s)
Preservación de Órganos , Trasplante de Órganos , Perfusión , Humanos , Preservación de Órganos/métodos , Preservación de Órganos/instrumentación , Trasplante de Órganos/métodos , Perfusión/métodos , Perfusión/instrumentación
18.
Gastroenterol Clin North Am ; 53(2): 281-288, 2024 06.
Artículo en Inglés | MEDLINE | ID: mdl-38719378

RESUMEN

The traditional procedure for multivisceral transplant (MVT) is to transplant the stomach, pancreas, intestine, and liver en bloc. During surgery, the native spleen is routinely removed from the recipient, and it usually creates more space in the abdomen to insert the allogeneic graft. Thus, recipients often become asplenic after MVT. Considering all of the risks and benefits, we advocate that temporary transplant of the donor spleen could be the best option for MVT recipients; it could potentially reduce the rate of intestinal allograft rejection without increasing the risk for graft-versus-host disease.


Asunto(s)
Intestinos , Bazo , Humanos , Rechazo de Injerto/prevención & control , Enfermedad Injerto contra Huésped/prevención & control , Enfermedad Injerto contra Huésped/etiología , Intestinos/trasplante , Trasplante de Órganos/métodos , Trasplante de Páncreas , Bazo/trasplante
19.
Gastroenterol Clin North Am ; 53(2): 245-264, 2024 06.
Artículo en Inglés | MEDLINE | ID: mdl-38719376

RESUMEN

Consensus remains elusive in the definition and indications of multivisceral transplantation (MVT) within the transplant community. MVT encompasses transplantation of all organs reliant on the celiac artery axis and the superior mesenteric artery in different combinations. Some institutions classify MVT as involving the grafting of the stomach or ascending colon in addition to the jejunoileal complex. MVT indications span a wide spectrum of conditions, including tumors, intestinal dysmotility disorders, and trauma. This systematic review aims to consolidate existing literature on MVT cases and their indications, providing an organizational framework to comprehend the current criteria for MVT.


Asunto(s)
Arteria Celíaca , Trasplante de Órganos , Humanos , Arteria Celíaca/cirugía , Trasplante de Órganos/métodos , Vísceras/trasplante , Abdomen/patología , Neoplasias/cirugía , Heridas y Lesiones/cirugía
20.
Cryo Letters ; 45(3): 139-148, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38709185

RESUMEN

It is some 50 years since the first published reports appeared of ex vivo preservation of organs for transplantation. Over the intervening decades, organ preservation strategies have become one essential component of world-wide clinical transplant services. In the formative years, translational research in organ hypothermic preservation was grappling with the questions about whether static or dynamic storage was preferable, and the practical implications of those choices. Those studies were also informing the newly expanding clinical transplant services. During the middle years, both preservation modalities were practiced by individual group choices. By the 2000s, the shift in donor demographics demanded a re-evaluation of organ preservation strategies, and now a new era of research and development is promoting adoption of new technologies. In this review we outline many important academic studies which have contributed to this successful history, and give profile to the increasing innovative approaches which are being evaluated for the future. Doi.org/10.54680/fr24310110112.


Asunto(s)
Criopreservación , Preservación de Órganos , Preservación de Órganos/métodos , Humanos , Criopreservación/métodos , Historia del Siglo XX , Trasplante de Órganos/métodos , Historia del Siglo XXI
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...